Literature DB >> 16356116

Peripheral nerve dysfunction in experimental diabetes is mediated by cyclooxygenase-2 and oxidative stress.

Aaron P Kellogg1, Rodica Pop-Busui.   

Abstract

Glucose-mediated oxidative stress and alterations in cyclooxygenase (COX) pathway activity with secondary deficits of endoneurial perfusion have been implicated in the pathogenesis of experimental diabetic neuropathy (EDN). We have previously reported that activation of the COX-2 pathway is an important mediator of neurochemical and neurovascular defects in EDN in a rat model. Considering that chemical COX inhibition may exert other pharmacological effects in addition to inhibition of COX activity, the aim of this study was to explore the role of COX-2 in experimental diabetic neuropathy, using a COX-2 knockout mouse model. Here we provide evidence that COX-2 inactivation had a protective effect against diabetes-induced motor and sensory nerve conduction slowing and impaired nerve antioxidative defense that were clearly manifest in the wild-type (COX-2(+/+)) diabetic mice. These preliminary data support the role of the activation of the COX-2 pathway in mediating sensory and motor nerve conduction velocity deficits in EDN. These findings also suggest that the COX-2 pathway seems to be an important modulator of oxidative stress in EDN. Antioxid. Redox Signal. 7, 1521-1529.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16356116     DOI: 10.1089/ars.2005.7.1521

Source DB:  PubMed          Journal:  Antioxid Redox Signal        ISSN: 1523-0864            Impact factor:   8.401


  19 in total

Review 1.  Early diabetic neuropathy: triggers and mechanisms.

Authors:  Maxim Dobretsov; Dmitry Romanovsky; Joseph R Stimers
Journal:  World J Gastroenterol       Date:  2007-01-14       Impact factor: 5.742

Review 2.  Diabetic peripheral neuropathy: should a chaperone accompany our therapeutic approach?

Authors:  Kevin L Farmer; Chengyuan Li; Rick T Dobrowsky
Journal:  Pharmacol Rev       Date:  2012-08-10       Impact factor: 25.468

Review 3.  Mouse models of diabetic neuropathy.

Authors:  Phillipe D O'Brien; Stacey A Sakowski; Eva L Feldman
Journal:  ILAR J       Date:  2014

4.  Associations Between Perceived Stress and Chemotherapy-Induced Peripheral Neuropathy and Otoxicity in Adult Cancer Survivors.

Authors:  Christine Miaskowski; Steven M Paul; Judy Mastick; Gary Abrams; Kimberly Topp; Betty Smoot; Kord M Kober; Margaret Chesney; Melissa Mazor; Grace Mausisa; Mark Schumacher; Yvette P Conley; Jennifer Henderson Sabes; Steven Cheung; Margaret Wallhagen; Jon D Levine
Journal:  J Pain Symptom Manage       Date:  2018-03-07       Impact factor: 3.612

5.  Mouse models of diabetic neuropathy.

Authors:  Kelli A Sullivan; John M Hayes; Timothy D Wiggin; Carey Backus; Sang Su Oh; Stephen I Lentz; Frank Brosius; Eva L Feldman
Journal:  Neurobiol Dis       Date:  2007-07-31       Impact factor: 5.996

Review 6.  Mechanisms of disease: the oxidative stress theory of diabetic neuropathy.

Authors:  Claudia Figueroa-Romero; Mahdieh Sadidi; Eva L Feldman
Journal:  Rev Endocr Metab Disord       Date:  2008-12       Impact factor: 6.514

Review 7.  Diabetic neuropathy: mechanisms to management.

Authors:  James L Edwards; Andrea M Vincent; Hsinlin T Cheng; Eva L Feldman
Journal:  Pharmacol Ther       Date:  2008-06-13       Impact factor: 12.310

8.  Increased tau phosphorylation and cleavage in mouse models of type 1 and type 2 diabetes.

Authors:  Bhumsoo Kim; Carey Backus; Sangsu Oh; John M Hayes; Eva L Feldman
Journal:  Endocrinology       Date:  2009-10-09       Impact factor: 4.736

Review 9.  Criteria for creating and assessing mouse models of diabetic neuropathy.

Authors:  Kelli A Sullivan; Stephen I Lentz; John L Roberts; Eva L Feldman
Journal:  Curr Drug Targets       Date:  2008-01       Impact factor: 3.465

10.  Effects of cyclooxygenase-2 gene inactivation on cardiac autonomic and left ventricular function in experimental diabetes.

Authors:  Aaron P Kellogg; Kimber Converso; Tim Wiggin; Martin Stevens; Rodica Pop-Busui
Journal:  Am J Physiol Heart Circ Physiol       Date:  2008-12-05       Impact factor: 4.733

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.